Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vanucizumab + mFOLFOX-6
- Development stage
- Discontinued
- Lead developer
- Roche
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Vanucizumab + mFOLFOX-6 is a combination regimen used in clinical trials for the first-line treatment of metastatic colorectal cancer. It consists of **vanucizumab**, a humanized IgG1-like bispecific monoclonal antibody that targets both vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2), combined with **modified FOLFOX-6 chemotherapy** (folinic acid [leucovorin], fluorouracil [5-FU], and oxaliplatin). Vanucizumab aims to block both VEGF-A and Ang-2 pathways to inhibit tumor angiogenesis and metastasis[4][6]. The combination was tested versus bevacizumab + mFOLFOX-6 in the phase II McCAVE trial. Although vanucizumab effectively engaged its intended targets, the trial found no superior benefit over anti–VEGF-A blockade alone. As a result, the further clinical development of this dual inhibitor was discontinued[6]. mFOLFOX-6 is a standard chemotherapy backbone given intravenously, with cycles incorporating oxaliplatin, leucovorin, and both bolus and infusion 5-FU[3][5][7].
- Other names
- vanucizumab + mFOLFOX-6
02
Targets
ANGPT2 (Angiopoietin-2)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on vanucizumab + mFOLFOX-6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vanucizumab + mFOLFOX-6.